DEVELOPMENT OF A NONTOXIC MULTIMODALITY CONTRAST AGENT

癌症是世界上主要的死亡原因之一。现在有 许多替代疗法已经被开发出来，并显示出希望。 成功的治疗通常取决于早期诊断。虽然 肿瘤与正常组织在病理上没有明显的区别 总物理性质的差异，直到它成为 触手可及。因此，三大医疗模式并没有 证明在识别小肿瘤方面取得了预期的成功。程序上的 成本在不断增加。这项建议关系到发展 一种通过静脉注射黏附于肿瘤的低成本药物 大量的血管壁，可以作为造影剂 三种主要的方式，超声波，X射线和磁共振成像。我们的作品 方法和材料成本将提供低成本的诊断试剂。 Microome建议扩展其现有的明胶微泡技术 到小的充气明胶微粒，其中含有X射线和 一名磁共振成像剂。建议的阶段活动包括创建8个 微米颗粒和建立浓度水平。第二阶段研究 将致力于将颗粒尺寸降低到3微米以下， 在动物模型和有限的临床病例中证明了它的有效性。

Cancer is one of the leading causes of death in the world. There are now many alternative treatments which have been developed and show promise. Successful treatment generally depends upon early diagnosis. Although tumors differ from normal tissue pathologically there are no significant differences in gross physical properties up to the point when it becomes palpable. Therefore the three major medical modalities have not demonstrated anticipated success in identifying small tumors. Procedural costs are continually increasing. This proposal concerns the development of a low-cost agent delivered via venous injection which adheres to tumor vessel walls in large numbers and can act as a contrast agent for all three major modalities, Ultrasound, X-ray and MR Imaging. Our production method and material costs will provide low cost diagnostic agents. Microsome proposes to extend its existing gelatin microbubble technology to small air-filled gelatin microparticles containing therein an X-ray and an MR Imaging agent. The proposed Phase activity consists of creating 8 micron particles and establishing concentration levels. Phase II studies would be oriented toward reducing particle size to less than 3 microns and demonstrating its efficacy in animal models and limited clinical cases.